Search

Your search keyword '"Johnson ECB"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Johnson ECB" Remove constraint Author: "Johnson ECB" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
37 results on '"Johnson ECB"'

Search Results

1. CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease.

2. Heparin-enriched plasma proteome is significantly altered in Alzheimer's disease.

3. Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer's disease.

4. Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer's disease.

5. Lower Prevalence of Asymptomatic Alzheimer's Disease Among Healthy African Americans.

6. Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease.

7. Proteomic analysis of Alzheimer's disease cerebrospinal fluid reveals alterations associated with APOE ε4 and atomoxetine treatment.

8. Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid.

9. Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.

10. Heparin-enriched plasma proteome is significantly altered in Alzheimer's Disease.

11. Systematic proteomics in Autosomal dominant Alzheimer's disease reveals decades-early changes of CSF proteins in neuronal death, and immune pathways.

12. Proteomic Changes in the Human Cerebrovasculature in Alzheimer's Disease and Related Tauopathies Linked to Peripheral Biomarkers in Plasma and Cerebrospinal Fluid.

13. Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer's disease.

14. Serum proteomics reveals APOE dependent and independent protein signatures in Alzheimer's disease.

15. Proteomic Network Analysis of Alzheimer's Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment.

16. Genetic background influences the 5XFAD Alzheimer's disease mouse model brain proteome.

17. Unbiased classification of the elderly human brain proteome resolves distinct clinical and pathophysiological subtypes of cognitive impairment.

18. A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease.

19. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.

20. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.

21. Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer's disease.

22. Genetic background influences the 5XFAD Alzheimer's disease mouse model brain proteome.

23. Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease.

24. Predictors of Cognitive Decline in Healthy Middle-Aged Individuals with Asymptomatic Alzheimer's Disease.

25. Batch Correction and Harmonization of -Omics Datasets with a Tunable Median Polish of Ratio.

26. Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.

27. CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels.

28. Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level.

29. Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis.

30. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease.

31. Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.

32. Identification of Conserved Proteomic Networks in Neurodegenerative Dementia.

33. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease.

34. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.

35. Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard.

36. Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease.

37. Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease.

Catalog

Books, media, physical & digital resources